You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Clinical Trials Assessment Statistics

Measuring the effect of the Clinical Trials Policy is a priority for us and the Ministry of Health and Long-Term Care. 

We publish clinical trial assessment outcomes and policy evaluation metrics on a regular basis.

 

Turnaround Times

 

*Measured in calendar days. Does not include the time when additional information is requested from the applicant.

 

 

 

 

 

Systemic Treatment-Quality Based Program Alignment

 

 

 

 

 

Provincial Drug Reimbursement Program Alignment

 

 

Turnaround Times

Clinical trial assessment turnaround times for applications assessed since January 2016
Measure Percentage Number
Percentage of assessments evaluated within 31 days 91% 1330
Percentage of assessments evaluated beyond 31 days 9% 137

This figure is titled 'Clinical trial assessment turnaround times' and is made up of a single pie chart. The turnaround times are measured in calendar days. They do not include the time when additional information is requested from the applicant.

The pie chart is made up of 2 slices. The first slice represents the percentage of assessments evaluated within 31 days which is 92%. The second slice represents the percentage of assessments evaluated beyond 31 days which is 8%.

Systemic Treatment-Quality Based Program Alignment

Distribution of clinical trial assessment outcomes that receive funding for the administration and delivery of systemic treatment through the Systemic Treatment-Quality Based Program (ST-QBP), for applications assessed since January 2016
Measure Percentage Number
Aligned to ST-QBP definition of a clinical trial 94% 1374
Not Aligned to ST-QBP definition of a clinical trial 6% 93

This figure is titled 'Distribution of clinical trial assessment outcomes that receive funding for the administration and delivery of systemic treatment through Systemic Treatment-Quality Based Program (ST-QBP) and is made up of a single pie chart.

The pie chart is made up of 2 slices. The first slice represents the percentage of assessments aligned to ST-QBP definition of a clinical trial which is 94%. The second slice represents the percentage of assessments not aligned to ST-QBP definition of a clinical trial which is 6%.

Provincial Drug Reimbursement Program Alignment

Distribution of clinical trial assessment outcomes for the purpose of public drug funding, for applications assessed since January 2016
Measure Percentage Number
Aligned for the purpose of drug funding 92% 1343
Partially aligned for the purpose of drug funding 5% 78
Not aligned for the purpose of drug funding 3% 46

This figure is titled 'Distribution of clinical trial assessment outcomes for the purpose of public drug funding' and is made up of a single pie chart.

The pie chart is made up of 3 slices. The first slice represents the percentage of assessments aligned for the purpose of drug funding which is 91%.

The second slice represents the percentage of assessments partially aligned for the purpose of drug funding, which is 3%. Some clinical trial applications request assessment for multiple publicly funded cancer drugs where some of the drugs are used in accordance with the existing drug funding policy i.e. "aligned" and some of the drugs are not used in accordance with the existing drug funding policy i.e. "not aligned". These clinical trial assessments are “partially aligned”.  

The third slice represents the percentage of assessments not aligned for the purpose of drug funding which is 6%.